Course Videos
Based on the results of the GENIE Consortium Project, what percentage of patients is estimated to be eligible for targeted therapy within the framework of precision cancer medicine, when evaluated with NGS?
What are the translational implications for NGS as you understand it from the results of the AACR/MSK GENIE Consortium project recently reported in Cancer Discovery?
What have we learned from the GENIE Consortium Project about discrepancies between mutational profiles identified in primary tumors comprising the TCGA database versus those observed in distributions identified by NGS in the GENIE project ...
What is the role of NGS, and role of fusion detection, in particular, in wild type EGFR NSCLC, non-squamous head and neck cancer, and glioblastoma?
How is NGS altering our understanding of the importance of combining, aggregating, and analyzing a full range of genomic data — from single mutations and alterations to fusion genes, copy number and RNA expression data — to guide therapeutic ...
In light of increasing evidence suggesting a relationship between total mutational burden and responsiveness to immune checkpoint inhibition, how are you positioning the role of hybrid capture-based whole exome NGS to guide precision-based cancer treatment?
What is the evolving role of NGS in identifying targeted therapies in the setting of metastatic colorectal cancer? Can you discuss this with a focus on BRAF mutations, HER2 amplification testing, and detection of microsatellite instability ...
Why is there a growing reliance among precision oncology specialists on full exome sequencing with NGS — such as that provided by FoundationOne Medicine — as opposed to targeted, hotspot panels? What critical information does the report provide?
What is the role of NGS in patients with triple-negative breast cancer? Is it controversial? Are there actionable insights than emerge from full exome sequencing in patients with TNBC who have progressed on standard therapies?
What is the role of hybrid capture-based NGS — full exome sequencing — for identifying targeted therapies in the setting of orphan cancers such as sarcoma? Can you cite some specific patient examples where NGS can offer actionable insights ...
How will hybrid capture-based NGS improve identification of patients with breast cancer who will benefit from trastuzumab therapy?
Can you provide an example of a luminal A patient with metastatic breast cancer in whom treatment was optimized by NGS-based, comprehensive genomic assessment?